---
document_datetime: 2026-01-20 17:50:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/agamree.html
document_name: agamree.html
version: success
processing_time: 0.1383412
conversion_datetime: 2026-01-20 20:30:31.856151
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Agamree

# Agamree

[RSS](/en/individual-human-medicine.xml/77407)

##### Authorised

This medicine is authorised for use in the European Union

vamorolone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Agamree](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-75398)
- [More information on Agamree](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Agamree is a medicine for treating Duchenne muscular dystrophy in patients from 4 years of age. Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function.

Duchenne muscular dystrophy is rare, and Agamree was designated an 'orphan medicine' (a medicine used in rare diseases) on 22 August 2014. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1309) .

Agamree contains the active substance vamorolone.

Expand section

Collapse section

## How is Agamree used?

The medicine can only be obtained with a prescription. Treatment should only be started by a specialist doctor with experience in managing Duchenne muscular dystrophy.

The medicine is available as a suspension to be taken by mouth once a day. The doctor will prescribe the dose based on the patient's bodyweight.

For more information about using Agamree, see the package leaflet or contact your doctor or pharmacist.

## How does Agamree work?

The active substance in Agamree, vamorolone, is a modified corticosteroid medicine and reduces inflammation by blocking the production of certain inflammatory substances called cytokines. The way it works in patients with Duchenne muscular dystrophy is not fully understood.

## What benefits of Agamree have been shown in studies?

A main study showed that Agamree was more effective than placebo (a dummy treatment) in treating Duchenne muscular dystrophy in patients between the ages of 4 and 7 years who were able to walk. The study, involving 121 patients, looked at their TTSTAND velocity (time to stand), which is the speed at which they can stand up from a lying position.

After 24 weeks of treatment, the average TTSTAND velocity increased from 0.19 to 0.24 rises per second in patients who took Agamree, while it decreased slightly from 0.20 to 0.19 rises per second in those who had placebo. This effect was maintained up to week 48.

## What are the risks associated with Agamree?

For the full list of side effects and restrictions with Agamree, see the package leaflet.

The most common side effects with Agamree (which may affect more than 1 in 10 people) include Cushingoid features (features caused by long-term use of a corticosteroid, such as fat build-up on the face and bruising), vomiting, increased weight and irritability.

The medicine must not be used in patients who have severely impaired liver function or who have recently received a live vaccine (a vaccine that uses a weakened form of the organism).

## Why is Agamree authorised in the EU?

The European Medicines Agency decided that Agamree's benefits are greater than its risks and it can be authorised for use in the EU.

The main study in patients between 4 and 7 years of age showed that Agamree is effective in improving their ability to move. Given that vamorolone works in the same way as currently used corticosteroids, the Agency concluded that it can be used in older patients as well.

In terms of safety, Agamree compares well with conventional corticosteroids and does not cause some of the side effects that conventional corticosteroids cause (such as effects on the bone and growth).

## What measures are being taken to ensure the safe and effective use of Agamree?

The company that markets Agamree will provide patients with an alert card with information about the need for daily treatment and the risk of adrenal crisis, a side effect which can occur in patients abruptly stopping corticosteroid treatment.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Agamree have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Agamree are continuously monitored. Suspected side effects reported with Agamree are carefully evaluated and any necessary action taken to protect patients.

## Other information about Agamree

Agamree received a marketing authorisation valid throughout the EU on 14 December 2023.

Agamree : EPAR - Medicine overview

Reference Number: EMA/489334/2023

English (EN) (108.05 KB - PDF)

**First published:** 04/01/2024

[View](/en/documents/overview/agamree-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-847)

български (BG) (132.75 KB - PDF)

**First published:**

04/01/2024

[View](/bg/documents/overview/agamree-epar-medicine-overview_bg.pdf)

español (ES) (107.97 KB - PDF)

**First published:**

04/01/2024

[View](/es/documents/overview/agamree-epar-medicine-overview_es.pdf)

čeština (CS) (129.15 KB - PDF)

**First published:**

04/01/2024

[View](/cs/documents/overview/agamree-epar-medicine-overview_cs.pdf)

dansk (DA) (108.13 KB - PDF)

**First published:**

04/01/2024

[View](/da/documents/overview/agamree-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.18 KB - PDF)

**First published:**

04/01/2024

[View](/de/documents/overview/agamree-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.7 KB - PDF)

**First published:**

04/01/2024

[View](/et/documents/overview/agamree-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132.84 KB - PDF)

**First published:**

04/01/2024

[View](/el/documents/overview/agamree-epar-medicine-overview_el.pdf)

français (FR) (109.21 KB - PDF)

**First published:**

04/01/2024

[View](/fr/documents/overview/agamree-epar-medicine-overview_fr.pdf)

hrvatski (HR) (128.16 KB - PDF)

**First published:**

04/01/2024

[View](/hr/documents/overview/agamree-epar-medicine-overview_hr.pdf)

italiano (IT) (108.02 KB - PDF)

**First published:**

04/01/2024

[View](/it/documents/overview/agamree-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.93 KB - PDF)

**First published:**

04/01/2024

[View](/lv/documents/overview/agamree-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (128.26 KB - PDF)

**First published:**

04/01/2024

[View](/lt/documents/overview/agamree-epar-medicine-overview_lt.pdf)

magyar (HU) (128.91 KB - PDF)

**First published:**

04/01/2024

[View](/hu/documents/overview/agamree-epar-medicine-overview_hu.pdf)

Malti (MT) (131.63 KB - PDF)

**First published:**

04/01/2024

[View](/mt/documents/overview/agamree-epar-medicine-overview_mt.pdf)

Nederlands (NL) (108.64 KB - PDF)

**First published:**

04/01/2024

[View](/nl/documents/overview/agamree-epar-medicine-overview_nl.pdf)

polski (PL) (132.79 KB - PDF)

**First published:**

04/01/2024

[View](/pl/documents/overview/agamree-epar-medicine-overview_pl.pdf)

português (PT) (109.28 KB - PDF)

**First published:**

04/01/2024

[View](/pt/documents/overview/agamree-epar-medicine-overview_pt.pdf)

română (RO) (124.41 KB - PDF)

**First published:**

04/01/2024

[View](/ro/documents/overview/agamree-epar-medicine-overview_ro.pdf)

slovenčina (SK) (128.96 KB - PDF)

**First published:**

04/01/2024

[View](/sk/documents/overview/agamree-epar-medicine-overview_sk.pdf)

slovenščina (SL) (126.75 KB - PDF)

**First published:**

04/01/2024

[View](/sl/documents/overview/agamree-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.56 KB - PDF)

**First published:**

04/01/2024

[View](/fi/documents/overview/agamree-epar-medicine-overview_fi.pdf)

svenska (SV) (106.94 KB - PDF)

**First published:**

04/01/2024

[View](/sv/documents/overview/agamree-epar-medicine-overview_sv.pdf)

Agamree : EPAR - Risk management plan

English (EN) (596.8 KB - PDF)

**First published:** 04/01/2024

**Last updated:** 15/11/2024

[View](/en/documents/rmp/agamree-epar-risk-management-plan_en.pdf)

## Product information

Agamree : EPAR - Product information

English (EN) (538.88 KB - PDF)

**First published:** 04/01/2024

**Last updated:** 20/01/2026

[View](/en/documents/product-information/agamree-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-462)

български (BG) (624.81 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/bg/documents/product-information/agamree-epar-product-information_bg.pdf)

español (ES) (561.79 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/es/documents/product-information/agamree-epar-product-information_es.pdf)

čeština (CS) (617.07 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/cs/documents/product-information/agamree-epar-product-information_cs.pdf)

dansk (DA) (544.01 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/da/documents/product-information/agamree-epar-product-information_da.pdf)

Deutsch (DE) (573.8 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/de/documents/product-information/agamree-epar-product-information_de.pdf)

eesti keel (ET) (554.24 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/et/documents/product-information/agamree-epar-product-information_et.pdf)

ελληνικά (EL) (629.81 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/el/documents/product-information/agamree-epar-product-information_el.pdf)

français (FR) (567.71 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/fr/documents/product-information/agamree-epar-product-information_fr.pdf)

hrvatski (HR) (604 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/hr/documents/product-information/agamree-epar-product-information_hr.pdf)

íslenska (IS) (566.22 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/is/documents/product-information/agamree-epar-product-information_is.pdf)

italiano (IT) (578.4 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/it/documents/product-information/agamree-epar-product-information_it.pdf)

latviešu valoda (LV) (633.08 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/lv/documents/product-information/agamree-epar-product-information_lv.pdf)

lietuvių kalba (LT) (621.82 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/lt/documents/product-information/agamree-epar-product-information_lt.pdf)

magyar (HU) (634.95 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/hu/documents/product-information/agamree-epar-product-information_hu.pdf)

Malti (MT) (667.27 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/mt/documents/product-information/agamree-epar-product-information_mt.pdf)

Nederlands (NL) (564.21 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/nl/documents/product-information/agamree-epar-product-information_nl.pdf)

norsk (NO) (532.05 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/no/documents/product-information/agamree-epar-product-information_no.pdf)

polski (PL) (634.99 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/pl/documents/product-information/agamree-epar-product-information_pl.pdf)

português (PT) (561.96 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/pt/documents/product-information/agamree-epar-product-information_pt.pdf)

română (RO) (616.24 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/ro/documents/product-information/agamree-epar-product-information_ro.pdf)

slovenčina (SK) (633.37 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/sk/documents/product-information/agamree-epar-product-information_sk.pdf)

slovenščina (SL) (624.99 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/sl/documents/product-information/agamree-epar-product-information_sl.pdf)

Suomi (FI) (552.27 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/fi/documents/product-information/agamree-epar-product-information_fi.pdf)

svenska (SV) (550.66 KB - PDF)

**First published:**

04/01/2024

**Last updated:**

20/01/2026

[View](/sv/documents/product-information/agamree-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290634 11/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Agamree : EPAR - All authorised presentations

English (EN) (40.21 KB - PDF)

**First published:** 04/01/2024

[View](/en/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-963)

български (BG) (57.51 KB - PDF)

**First published:**

04/01/2024

[View](/bg/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.27 KB - PDF)

**First published:**

04/01/2024

[View](/es/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.08 KB - PDF)

**First published:**

04/01/2024

[View](/cs/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.08 KB - PDF)

**First published:**

04/01/2024

[View](/da/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.37 KB - PDF)

**First published:**

04/01/2024

[View](/de/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.83 KB - PDF)

**First published:**

04/01/2024

[View](/et/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.94 KB - PDF)

**First published:**

04/01/2024

[View](/el/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_el.pdf)

français (FR) (41.27 KB - PDF)

**First published:**

04/01/2024

[View](/fr/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.08 KB - PDF)

**First published:**

04/01/2024

[View](/hr/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.51 KB - PDF)

**First published:**

04/01/2024

[View](/is/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_is.pdf)

italiano (IT) (40.5 KB - PDF)

**First published:**

04/01/2024

[View](/it/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.27 KB - PDF)

**First published:**

04/01/2024

[View](/lv/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.09 KB - PDF)

**First published:**

04/01/2024

[View](/lt/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (59.55 KB - PDF)

**First published:**

04/01/2024

[View](/hu/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.96 KB - PDF)

**First published:**

04/01/2024

[View](/mt/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.83 KB - PDF)

**First published:**

04/01/2024

[View](/nl/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.56 KB - PDF)

**First published:**

04/01/2024

[View](/no/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.63 KB - PDF)

**First published:**

04/01/2024

[View](/pl/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_pl.pdf)

português (PT) (41.44 KB - PDF)

**First published:**

04/01/2024

[View](/pt/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.28 KB - PDF)

**First published:**

04/01/2024

[View](/ro/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.03 KB - PDF)

**First published:**

04/01/2024

[View](/sk/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.25 KB - PDF)

**First published:**

04/01/2024

[View](/sl/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.92 KB - PDF)

**First published:**

04/01/2024

[View](/fi/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (40.98 KB - PDF)

**First published:**

04/01/2024

[View](/sv/documents/all-authorised-presentations/agamree-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Agamree Active substance vamorolone International non-proprietary name (INN) or common name vamorolone Therapeutic area (MeSH) Muscular Dystrophy, Duchenne Anatomical therapeutic chemical (ATC) code H02AB18

### Pharmacotherapeutic group

Glucocorticoids

### Therapeutic indication

Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.

## Authorisation details

EMA product number EMEA/H/C/005679

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Santhera Pharmaceuticals (Deutschland) GmbH

Marie-Curie Strasse 8

Opinion adopted 12/10/2023 Marketing authorisation issued 14/12/2023 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Agamree : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (175.38 KB - PDF)

**First published:** 16/12/2025

**Last updated:** 20/01/2026

[View](/en/documents/procedural-steps-after/agamree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Agamree : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (149.88 KB - PDF)

**First published:** 13/05/2024

**Last updated:** 16/12/2025

[View](/en/documents/procedural-steps-after/agamree-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Agamree : Orphan maintenance assessment report - initial authorisation

Adopted

Reference Number: EMA/OD/0000141144

English (EN) (299.47 KB - PDF)

**First published:** 04/01/2024

[View](/en/documents/orphan-maintenance-report/agamree-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Agamree : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/487504/2023

English (EN) (2.36 MB - PDF)

**First published:** 04/01/2024

[View](/en/documents/assessment-report/agamree-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Agamree

Adopted

Reference Number: EMA/CHMP/458203/2023EMA/CHMP/458203/2023

English (EN) (159.17 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-agamree_en.pdf)

#### News on Agamree

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Agamree : EPAR - Product information - tracked changes

English (EN) (277.88 KB - DOCX)

**First published:** 25/03/2025

**Last updated:** 20/01/2026

[View](/en/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-379)

български (BG) (293.6 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/bg/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_bg.docx)

español (ES) (232.24 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/es/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_es.docx)

čeština (CS) (231.48 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/cs/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (225.08 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/da/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (287.2 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/de/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (280.11 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/et/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (242.96 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/el/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_el.docx)

français (FR) (233.63 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/fr/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (232.7 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/hr/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (233.22 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/is/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_is.docx)

italiano (IT) (230.06 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/it/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (286.33 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/lv/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (286.39 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/lt/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (239.12 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/hu/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (281.36 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/mt/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (234.34 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/nl/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (231.62 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/no/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_no.docx)

polski (PL) (284.46 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/pl/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_pl.docx)

português (PT) (236.83 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/pt/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_pt.docx)

română (RO) (285.49 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/ro/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (234.84 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/sk/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (235.89 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/sl/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (236.97 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/fi/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (274.16 KB - DOCX)

**First published:**

25/03/2025

**Last updated:**

20/01/2026

[View](/sv/documents/product-information-tracked-changes/agamree-epar-product-information-tracked-changes_sv.docx)

#### More information on Agamree

- [EU/3/14/1309 - orphan designation for treatment of Duchenne muscular dystrophy](/en/medicines/human/orphan-designations/eu-3-14-1309)
- [EMEA-001794-PIP02-16-M09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001794-pip02-16-m09)

**This page was last updated on** 20/01/2026

## Share this page

[Back to top](#main-content)